Organisation paid for research Program year 2025 Source: CMS Open Payments

Children's Specialty Group PLLC

Neither a doctor nor a teaching hospital

Research payments

$594,750

178 payments

Through program year 2025, Children's Specialty Group PLLC is reported as receiving $594,750 in research payments, across 178 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $26,450 14
2024 Research $28,407 8
2023 Research $307,512 39
2022 Research $177,099 96
2021 Research $36,856 12
2020 Research $18,382 8
2019 Research $46 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $221,426 121 payments
  2. Amgen Inc. $171,248 6 payments
  3. Neurelis, Inc. $96,611 10 payments
  4. PTC Therapeutics, Inc. $35,129 15 payments
  5. BioMarin Pharmaceutical Inc. $21,398 6 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $18,620 9 payments
  7. AbbVie, Inc. $11,813 1 payment
  8. Biohaven Pharmaceutical Holding Company Ltd. $8,736 3 payments
  9. Exeltis, USA Inc. $5,622 5 payments
  10. SpringWorks Therapeutics, Inc. $4,104 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $131,419 85 payments
  2. An Open-Label, Single-Dose, Pharmacokinetics Study of Valtoco With Open-Label Safety Period in Pediatric Subjects With Epilepsy $96,611 10 payments
  3. Phase P3 Pediatric Study (EM) $91,185 2 payments
  4. Ph3 Pediatric CM Study $70,043 2 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age $58,372 21 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $31,635 15 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension $21,396 9 payments
  8. Morquio A Registry Study MARS) $18,558 4 payments
  9. Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. $11,813 1 payment
  10. A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (Ee) and Maintenance of Healed Ee in Pediatric Subjects Aged 1 to 11 Years With Ee $9,670 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record